Unusual location of recurrent mantle cell lymphoma on fluorodeoxyglucose-positron emission tomography despite complete metabolic resolution of previous sites of disease

Benjamin Froitzheim; Raef Boktor; Eddie Lau; Sze Lee

doi:10.4103/wjnm.WJNM_65_19

World Journal of Nuclear Medicine, Table of Contents

CC BY-NC-ND 4.0 · World J Nucl Med 2020; 19(03): 277-280
DOI: 10.4103/wjnm.WJNM_65_19

Case Report

Unusual location of recurrent mantle cell lymphoma on fluorodeoxyglucose-positron emission tomography despite complete metabolic resolution of previous sites of disease

Authors

Benjamin Froitzheim

¹University of Regensburg, Regensburg, Germany

²Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia
Raef Boktor

²Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia
Eddie Lau

²Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia

³Department of Radiology, Austin Health, Heidelberg, Victoria

⁴Department of Medicine, University of Melbourne, Melbourne
Sze Lee

²Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia

⁵Olivia Newton-John Cancer Research Institute, Austin Health

⁶School of Cancer Medicine, LaTrobe University, Melbourne, Australia

Abstract

This case report presents a patient with recurrent pleomorphic mantle cell lymphoma (MCL), which is a relatively rare but aggressive type of lymphoma. A positron emission tomography/computed tomography scan performed to assess treatment response demonstrated a complete metabolic response in the sites of primary disease while also revealing new subcutaneous lesions, which were biopsy-proven recurrent disease. This case illustrates the importance of the different biological behavior of MCL, whereby new sites of metabolically active lesions can represent recurrent disease, even though there is a complete metabolic response at sites of primary disease.

Keywords

Fluorodeoxyglucose-positron emission tomography/computed tomography - mantle cell lymphoma - recurrent lymphoma - treatment response

Full Text

References

References
1 Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood 2016;127:2375-90.
2 A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. The non-Hodgkin's lymphoma classification project. Blood 1997;89:3909-18.
3 Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. Anew prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558-65.
4 Swerdlow SH, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer; 2008.
5 Klener P. Advances in molecular biology and targeted therapy of mantle cell lymphoma. Int J Mol Sci 2019;20:4417.
6 Baba S, Abe K, Isoda T, Maruoka Y, Sasaki M, Honda H. Impact of FDG-PET/CT in the management of lymphoma. Ann Nucl Med 2011;25:701-16.
7 Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16:1514-23.
8 Bailly C, Carlier T, Touzeau C, Arlicot N, Kraeber-Bodéré F, Le Gouill S, et al. Interest of FDG-PET in the management of mantle cell lymphoma. Front Med (Lausanne) 2019;6:70.
9 Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma 2009;50:1257-60.
10 Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol 2014;32:3059-68.
11 Metser U, Tau N. Benign cutaneous and subcutaneous lesions on FDG-PET/CT. Semin Nucl Med 2017;47:352-61.